Industry data shows that drugs with more than 10 years of exclusivity remaining typically transact at 5x to 8x peak sales
Tirzepatide carries the CAS number 2023788-19-2 and a molecular formula of C225H348N48O68
Over 68 weeks, with a starting dose of 2 mg escalated every 4 weeks: 9 mg dose: 26.4% average body weight reduction (29.1 kg / 64.2 lbs) 12 mg dose: 28.7% average body weight reduction (32.3 kg / 71.2 lbs) Placebo: 2.1% average body weight reduction The milestone achievements tell an even more compelling story
Systematic site rotation with each weekly injection, proper injection technique including allowing medication to reach room temperature, and thorough skin preparation with alcohol swabs are the most effective prevention strategies for minimizing injection site reactions
IcoSema is a subcutaneous once-weekly fixed-ratio combination of insulin icodec and semaglutide and is currently in phase 3 development
Current serotonin medications are aimed at increasing central 5-HT neurotransmission in the brain, and there are no approved indications for manipulating peripheral 5-HT, though peripheral 5-HT synthesis is being considered as a potential target for developing pharmacological agents in some disorders (8, 9)
